Abstract
The Interleukin 10 (IL-10) gene is highly polymorphic, and the IL-10−1087AG (rs1800896) gene variation is the only so far studied intensively in association with certain diseases. Conflicting data have been published about an association of IL-10−1087AG gene variation with lower rates of complete remission and lower overall survival (OS) in patients with diffuse large B-cell lymphoma. To further investigate this in malignant lymphoma, we established the IL-10 genotypes in patients from the NHL-B1/ B2 studies from the German High-Grade Non-Hodgkin's Lymphoma Study Group. In our study, allele frequencies of lymphoma patients are comparable as in healthy controls. No increase of IL-10–1087G alleles was found. In addition we did not find any difference in OS or event-free survival between patients with IL-10–1087AA and the other genotypes. Comparable results were obtained for the IL-10 loci at −3538 (A/T), −1354 (A/G), −824 (C/T) and −597 (A/C) (rs1800890, rs1800893, rs1800871 and rs1800872).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Moore KW, de Waal Malefyt R, Coffman RL et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683–765.
Cortes JE, Talpaz M, Cabanillas F et al. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 1995; 85: 2516–2520.
Stasi R, Zinzani PL, Galieni P et al. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 1994; 88: 770–777.
Blay JY, Burdin N, Rousset F et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993; 82: 2169–2174.
Burdin N, Rousset F, Banchereau J . B-cell-derived IL-10: production and function. Methods 1997; 11: 98–111.
Keystone E, Wherry J, Grint P . IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheumatic Dis Clin 1998; 24: 629–639.
Ferraccioli G, Falleti E, DeVita S et al. Circulating levels of interleukin 10 and other cytokines in rheumatoid arthritis treated with cyclosporin A or combination therapy. J Rheum 1998; 25: 1874–1879.
Ho M, Schollaardt T, Snape S et al. Endogenous interleukin-10 modulates proinflammatory response in Plasmodium falciparum malaria. J Infect Dis 1998; 178: 520–525.
Sarris AH, Kliche KO, Pethambaram P et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 1999; 10: 433–440.
Goldman M, Velu T, Pretolani M . Interleukin-10. Actions and therapeutic potential. BioDrugs 1997; 7: 6–14.
Lalani I, Bhol K, Ahmed A . Interleukin-10: biology, role in inflammation and autoimmunity. Ann All Asth Immunol 1997; 79: 469–484.
Narula SK, Cutler D, Grint P . Immunomodulation of Crohn's disease by Interleukin-10. Agents and Actions Suppl 1998; 49: 57–65.
Van Deventer SJ . Immunotherapy of Crohn's disease. Scand JImmunol 2000; 51: 18–22.
Cavet J, Middleton P, Segall M et al. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999; 94: 3941–3946.
Hollegaard MV, Bidwell JL . Cytokine gene polymorphism in human disease: on-line databases, Supplement 3. Genes Immun 2006; 7: 269–276.
Turner D, Williams D, Sankaran D et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogen 1997; 24: 1–8.
Westendorp R, Langermans J, Huizinga T et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170–173.
Gibson AW, Edberg JC, Wu J et al. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001; 166: 3915–3922.
Eskdale J, Gallagher G, Verweij C et al. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95: 9465–9470.
Crawley E, Kay R, Sillibourne J et al. Polymorphic haplotypes of the IL-10 5′ flanking region determine variable IL-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthr Rheum 1999; 42: 1101–1108.
Mormann M, Rieth H, Hua TD et al. Mosaics of gene variations in the Interleukin-10 gene promoter affect interleukin-10 production depending on the stimulation used. Genes Immun 2004; 5: 246–255.
Lech-Maranda E, Baseggio L, Bienvenu J et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004; 103: 3529–3534.
Berglund M, Thunberg U, Roos G et al. The interleukin-10 gene promoter polymorphism (−1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. Blood 2005; 105: 4894–4895 and author reply 4895.
Rothman N, Skibola CF, Wang SS et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006; 7: 27–38.
Nieters A, Beckmann L, Deeg E et al. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006; 7: 615–624.
Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634–641.
Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626–633.
Wojnowski L, Kulle B, Schirmer M et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112: 3754–3762.
Im SH, Hueber A, Monticelli S et al. Chromatin-level regulation of the IL10 gene in T cells. J Biol Chem 2004; 279: 46818–46825.
Zhang X, Edwards JP, Mosser DM . Dynamic and transient remodeling of the macrophage IL-10 promoter during transcription. J Immunol 2006; 177: 1282–1288.
Wang ZY, Sato H, Kusam S et al. Regulation of IL-10 gene expression in Th2 cells by Jun proteins. J Immunol 2005; 174: 2098–2105.
Shoemaker J, Saraiva M, O'Garra A . GATA-3 directly remodels the IL-10 locus independently of IL-4 in CD4+ T cells. J Immunol 2006; 176: 3470–3479.
Saraiva M, Christensen JR, Tsytsykova AV et al. Identification of a macrophage-specific chromatin signature in the IL-10 locus. J Immunol 2005; 175: 1041–1046.
Lucas M, Zhang X, Prasanna V et al. ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol 2005; 175: 469–477.
Jones EA, Flavell RA . Distal enhancer elements transcribe intergenic RNA in the IL-10 family gene cluster. J Immunol 2005; 175: 7437–7446.
Lan Q, Zheng T, Rothman N et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006; 107: 4101–4108.
Acknowledgements
The authors are gratefull to the Deutsche Forschnugsgemeinschaft (Graduiertenkolleg 1034), the BMBF (NGFN-1) and the Deutsche Krebshilfe/BMBF (NHL-B) for supporting this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kube, D., Hua, TD., Klöss, M. et al. The interleukin-10 gene promoter polymorphism −1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma. Genes Immun 8, 164–167 (2007). https://doi.org/10.1038/sj.gene.6364364
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gene.6364364
Keywords
This article is cited by
-
Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP
Annals of Hematology (2017)
-
Association of Interleukin-10 −3575T>A and −1082A>G polymorphisms with non-Hodgkin lymphoma susceptibility: a comprehensive review and meta-analysis
Molecular Genetics and Genomics (2015)
-
Association of interleukin-10, tumor necrosis factor-α and transforming growth factor-β gene polymorphisms with the outcome of diffuse large B-cell lymphomas
International Journal of Clinical Oncology (2014)